相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Razvan Cristescu et al.
CLINICAL CANCER RESEARCH (2022)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (vol 38, pg 500, 2020)
Catherine S. Grasso et al.
CANCER CELL (2021)
Wnt/beta-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
Alexander Chehrazi-Raffle et al.
CANCERS (2021)
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas et al.
NATURE CANCER (2021)
Wnt Signaling and Drug Resistance in Cancer
Zheng Zhong et al.
MOLECULAR PHARMACOLOGY (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy
Razvan Cristescu et al.
CANCER RESEARCH (2020)
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
Wenting Liao et al.
CANCER CELL (2019)
Targeted Therapy and Immunotherapy for Melanoma in Japan
Kenjiro Namikawa et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
A Review of the Role of Wnt in Cancer Immunomodulation
Whitney N. Goldsberry et al.
CANCERS (2019)
Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients
T. Maeda et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2019)
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Bagher Farhood et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Targeted Genomic Profiling of Acral Melanoma
Iwei Yeh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Elena Martin-Orozco et al.
FRONTIERS IN IMMUNOLOGY (2019)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Omid Hamid et al.
BRITISH JOURNAL OF CANCER (2018)
Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study
Yoshiyuki Nakamura et al.
JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
Kenjiro Namikawa et al.
EUROPEAN JOURNAL OF CANCER (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated withReducedImmuneInfiltrationandReactivity in Colorectal Cancer
Neeraj Lal et al.
CLINICAL CANCER RESEARCH (2018)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Analysis of Trends in US Melanoma Incidence and Mortality
Alex M. Glazer et al.
JAMA DERMATOLOGY (2017)
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Dendritic cells in cancer: the role revisited
Filippo Veglia et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
Deborah Kuk et al.
ONCOLOGIST (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
PureCN: copy number calling and SNV classification using targeted short read sequencing
Markus Riester et al.
SOURCE CODE FOR BIOLOGY AND MEDICINE (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Prognosis of Acral Melanoma: A Series of 281 Patients
Danielle M. Bello et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Nancy E. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
OSA: a fast and accurate alignment tool for RNA-Seq
Jun Hu et al.
BIOINFORMATICS (2012)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
Domenico Coppola et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response
Dung T. Le et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Gene Signature in Melanoma Associated With Clinical Activity A Potential Clue to Unlock Cancer Immunotherapy
Thomas F. Gajewski et al.
CANCER JOURNAL (2010)
CD11c(+)CD8(+) T cells: Two-faced adaptive immune regulators
Dass S. Vinay et al.
CELLULAR IMMUNOLOGY (2010)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Environmental exposures and mutational patterns of cancer genomes
Gerd P. Pfeifer
GENOME MEDICINE (2010)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus
Damien Chaussabel et al.
IMMUNITY (2008)
Interferon-alpha in tumor immunity and immunotherapy
F Belardelli et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
分享论文
